[ad_1]
SEOUL, South Korea, Nov. 29, 2022 /PRNewswire/ — At the World Congress for Hair Research 2022 (Melbourne, Australia), Yuyu Pharma shared its plans to conduct medical trials within the U.S. and Europe for its Dutasteride Tablet (“DUT”) for the remedy of Androgenetic Alopecia (“AGA”).
DUT was developed to enhance the comfort and luxury for sufferers by making a pill smaller in measurement whereas maintaining the very same dosage of 0.5mg. There are plans to have a pre-IND assembly with the U.S. FDA and Scientific Advice assembly with Europe’s EMA subsequent 12 months.
Dutasteride inhibits each Type I and Type II 5-alpha reductase which act to remodel testosterone, a male hormone, right into a DHT hormone. In scientific research, extra DHT is known to be the reason for hair loss.
Wonsang Robert Yu, CEO of Yuyu Pharma stated “Dutasteride has been approved and is prescribed to patients with AGA in Korea and Japan. But it is not approved as a hair loss treatment in the U.S. and Europe. We hope to do trials to get AGA on-label in both US and Europe.”
About Yuyu Pharma
Yuyu Pharma (KRX: 000220) is a Korean pharmaceutical firm based in 1941 that manufactures and distributes pharmaceutical merchandise, medical gadgets, and meals dietary supplements. The firm can be dedicated to growing progressive therapeutics within the areas of Neurology, Urology, and Ophthalmology. Yuyu’s Mission is to enhance the standard of life and improve well-being for all people by growing progressive healthcare services and products.
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/yuyu-pharma-plans-to-enter-the-us-and-european-markets-for-hair-loss-treatment-301688588.html
SOURCE Yuyu Pharma
window.fbAsyncInit = function()
FB.init(
appId : ‘415409898518774’, // App ID
channelUrl : ‘//www.streetinsider.com/fbchannel.php’, // Channel File
status : true, // check login status
cookie : true, // enable cookies to allow the server to access the session
xfbml : true, // parse XFBML
oauth : true,
version : ‘v2.5’
);
// Additional initialization code here
FB.Event.subscribe(‘auth.statusChange’, function(response)
if ( response.status == ‘connected’ )
if ( window.fbLoginCallback )
window.fbLoginCallback.call(window, response);
);
FB.Event.subscribe(‘edge.create’, function(e)
if ( window.onFbLike )
window.onFbLike();
);
;
// Load the SDK Asynchronously
(function(d)
var js, id = ‘facebook-jssdk’, ref = d.getElementsByTagName(‘script’)[0];
if (d.getElementById(id)) return;
js = d.createElement(‘script’); js.id = id; js.async = true; js.defer = true;
js.src = “https://connect.facebook.net/en_US/all.js”;
ref.parentNode.insertBefore(js, ref);
(document));
[ad_2]
Source by [author_name]